1. IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer
- Author
-
Nikolaos Pazaitis, Christian Ihling, Hans-Georg Strauss, O Ungurs, Simon Müller, Annekatrin Schott, Christoph Thomssen, Andrea Sinz, Claudia Wickenhauser, Chris Alexander Aßmann, Marcell Lederer, Danny Misiak, Markus Glaß, Nadine Bley, Tommy Fuchs, Martina Vetter, and Stefan Hüttelmaier
- Subjects
MAPK/ERK pathway ,Stimulation ,ERK2 ,Mice ,0302 clinical medicine ,Ovarian carcinoma ,signalling ,Internalization ,media_common ,Ovarian Neoplasms ,0303 health sciences ,IGF2BP1 ,Chemistry ,RNA-Binding Proteins ,Adherens Junctions ,invasion ,Gene Expression Regulation, Neoplastic ,Serous fluid ,src-Family Kinases ,030220 oncology & carcinogenesis ,Female ,Mitogen-Activated Protein Kinases ,Research Article ,Research Paper ,SRC ,Protein Binding ,Signal Transduction ,Proto-oncogene tyrosine-protein kinase Src ,Epithelial-Mesenchymal Transition ,media_common.quotation_subject ,Biology ,resistance ,src Homology Domains ,Adherens junction ,03 medical and health sciences ,Cell Line, Tumor ,Biomarkers, Tumor ,medicine ,Animals ,Humans ,Protein Interaction Domains and Motifs ,Protein Kinase Inhibitors ,Molecular Biology ,selumetinib ,030304 developmental biology ,Cell Biology ,medicine.disease ,Xenograft Model Antitumor Assays ,Disease Models, Animal ,Cancer research ,Selumetinib ,saracatinib ,Ovarian cancer - Abstract
Epithelial-to-mesenchymal transition (EMT) is a hallmark of aggressive, mesenchymal-like high-grade serous ovarian carcinoma (HG-SOC). The SRC kinase is a key driver of cancer-associated EMT promoting adherens junction (AJ) disassembly by phosphorylation-driven internalization and degradation of AJ proteins. Here we show, that the IGF2 mRNA binding protein 1 (IGF2BP1) is up-regulated in mesenchymal-like HG-SOC and promotes SRC activation by a previously unknown protein-ligand-induced, but RNA-independent mechanism. IGF2BP1-driven invasive growth of ovarian cancer cells essentially relies on the SRC-dependent disassembly of AJs. Concomitantly, IGF2BP1 enhances ERK2 expression in a RNA-binding dependent manner. Together this reveals a post-transcriptional mechanism of interconnected stimulation of SRC/ERK signaling in ovarian cancer cells. The IGF2BP1-SRC/ERK2 axis is targetable by the SRC-inhibitor saracatinib and MEK-inhibitor selumetinib. However, due to IGF2BP1-directed stimulation only combinatorial treatment effectively overcomes the IGF2BP1-promoted invasive growth in 3D culture conditions as well as intraperitoneal mouse models. In conclusion, we reveal an unexpected role of IGF2BP1 in enhancing SRC/MAPK-driven invasive growth of ovarian cancer cells. This provides a rational for the therapeutic benefit of combinatorial SRC/MEK inhibition in mesenchymal-like HG-SOC.Graphical Abstract
- Published
- 2020
- Full Text
- View/download PDF